Health Care & Life Sciences » Biotechnology | Arena Pharmaceuticals Inc.

Arena Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
221,878.00
163,209.00
156,184.00
90,712.00
247,077.00
445,631
Total Accounts Receivable
10,602.00
3,712.00
4,934.00
573.00
14,382.00
5,086
Inventories
12,759.00
10,831.00
9,502.00
-
-
-
Other Current Assets
3,571.00
4,144.00
4,218.00
28,604.00
19,821.00
10,008
Total Current Assets
248,810.00
181,896.00
174,838.00
119,889.00
281,280.00
460,725
Net Property, Plant & Equipment
77,388.00
82,919.00
71,828.00
35,109.00
30,131.00
23,114
Total Investments and Advances
-
-
-
-
24,242.00
82,412
Intangible Assets
10,182.00
8,482.00
7,775.00
-
-
-
Other Assets
3,427.00
3,088.00
2,351.00
14,012.00
3,622.00
10,319
Total Assets
339,807.00
276,385.00
256,792.00
169,010.00
339,275.00
686,903
ST Debt & Current Portion LT Debt
2,056.00
2,492.00
2,978.00
3,518.00
4,000.00
Accounts Payable
23,026.00
26,549.00
14,158.00
1,295.00
1,599.00
Other Current Liabilities
45,662.00
38,321.00
32,760.00
59,066.00
66,728.00
Total Current Liabilities
70,744.00
67,362.00
49,896.00
63,879.00
72,327.00
Long-Term Debt
70,738.00
68,245.00
65,267.00
61,748.00
57,748.00
Other Liabilities
106,468.00
93,433.00
88,087.00
2,988.00
2,056.00
Total Liabilities
247,950.00
229,040.00
203,250.00
128,615.00
132,131.00
Common Equity (Total)
91,857.00
47,345.00
53,542.00
39,904.00
207,144.00
Total Shareholders' Equity
91,857.00
47,345.00
53,542.00
39,904.00
207,144.00
Total Equity
91,857.00
47,345.00
53,542.00
40,395.00
207,144.00
Liabilities & Shareholders' Equity
339,807.00
276,385.00
256,792.00
169,010.00
339,275.00
Accumulated Minority Interest
-
-
-
491.00
-

About Arena Pharmaceuticals

View Profile
Address
6154 Nancy Ridge Drive
San Diego California 92121
United States
Employees -
Website http://www.arenapharm.com
Updated 07/08/2019
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P.